Abstract
Modern chemotherapy for lymphoma and solid tissue malignancy is most frequently administered in a cyclical fashion on an outpatient basis over many months. During this time patients have a significant risk of developing severe neutropenia due to the myelotoxic effects of the treatment regimens; this increases the risk of potentially life-threatening infection. The risk of grade IV neutropenia (<0.5 x 10(9)/L) ranges from approximately 20% to >70% depending upon the cytotoxic potential of the regimen. The risks of infection associated with severe neutropenia range from approximately 10-20% to >50%. Haematopoietic growth factors have had only minimal impact on these risks and on the natural history of febrile neutropenic events that occur during the course of cancer chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
